Tenecteplase, given as a standard dose in an injection, is being trialled ahead of its cousin, 25-year-old alteplase, which requires a time-consuming one-hour infusion and has been found to work for only 30 to 45 per cent of patients.
#Clot buster for stroke trial#
The trial on the Melbourne stroke ambulance is the first pre-hospital trial of Tenecteplase for stroke in the world. Tenecteplase, is chemically related to a protein that is found in the blood called tissue-plasminogen activator, and binds to blood clots and dissolves them rapidly, removing artery blockages and returning blood flow to the brain.
When diagnosed as requiring thrombolysis, patients may receive a potentially more effective clot-buster, Tenecteplase. Patients are CT-scanned in a specialist stroke ambulance. The two-year study, led by the University of Melbourne (and including Melbourne Academic Centre for Health (MACH) partners Austin Health, The Florey Institute of Neuroscience and Mental Health, Melbourne Health, St Vincent’s Hospital Melbourne, and Western Health) is still in progress and is expected to complete recruitment and follow-up by the end of 2021. It is hoped the research will lead to life-changing outcomes for people with ischaemic stroke (85% of all strokes) who require a clot-busting medication within a strict treatment window – in a range of settings including specialist stroke centres and emergency departments. A new generation of clot-busting medication may lead to a change in standard medical practice in stroke treatment centres around Australia, thanks to research being conducted onboard Melbourne’s specialist stroke ambulance.
0 kommentar(er)
